Chirizzi Cristina, Pellegatta Serena, Gori Alessandro, Falco Jacopo, Rubiu Emanuele, Acerbi Francesco, Bombelli Francesca Baldelli
Department of Chemistry, Materials and Chemical Engineering "Giulio Natta" Politecnico di Milano Milano Italy.
Unit of Immunotherapy of Brain Tumors Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy.
Bioeng Transl Med. 2023 Oct 11;9(3):e10608. doi: 10.1002/btm2.10608. eCollection 2024 May.
Glioblastoma is a fast-growing and aggressive form of brain cancer. Even with maximal treatment, patients show a low median survival and are often subjected to a high recurrence incidence. The currently available treatments require multimodal management, including maximal safe surgical resection, followed by radiation and chemotherapy. Because of the infiltrative glioblastoma nature, intraoperative differentiation of cancer tissue from normal brain parenchyma is very challenging, and this accounts for the low rate of complete tumor resection. For these reasons, clinicians have increasingly used various intraoperative adjuncts to improve surgical results, such as fluorescent agents. However, most of the existing fluorophores show several limitations such as poor selectivity, photostability, photosensitization and high costs. This could limit their application to successfully improve glioblastoma resection. In the present perspective, we highlight the possibility to develop next-generation fluorescent tools able to more selectively label cancer cells during surgical resection.
胶质母细胞瘤是一种生长迅速且具有侵袭性的脑癌形式。即使进行最大程度的治疗，患者的中位生存期仍较低，且复发率往往较高。目前可用的治疗方法需要多模式管理，包括最大程度的安全手术切除，随后进行放疗和化疗。由于胶质母细胞瘤具有浸润性，术中区分癌组织与正常脑实质极具挑战性，这也是肿瘤完全切除率低的原因。基于这些原因，临床医生越来越多地使用各种术中辅助手段来改善手术效果，如荧光剂。然而，现有的大多数荧光团存在一些局限性，如选择性差、光稳定性差、光敏性和成本高。这可能会限制它们在成功改善胶质母细胞瘤切除方面的应用。在本观点中，我们强调了开发下一代荧光工具的可能性，这些工具能够在手术切除过程中更有选择性地标记癌细胞。
